Lower pharmacokinetic and pharmacodynamic within-day variability of individual clinical doses of insulin glargine 300 U/ml vs glargine 100 U/ml in type 1 diabetes

被引：0
|
作者：
Fanelli, C. G. [1 ]
Lucidi, P. [1 ]
Candeloro, P. [1 ]
Cioli, P. [1 ]
Andreoli, A. Marinelli [1 ]
Bolli, G. B. [1 ]
Porcellati, F. [1 ]
机构：
[1] Univ Perugia, Perugia, Italy
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
833
引用
收藏
页码：S409 / S409
页数：1
相关论文
共 50 条
  • [1] Lower Pharmacokinetic and Pharmacodynamic Within-Day Variability of Individual Clinical Doses of Insulin Glargine 300 U/ml vs. Glargine 100 U/ml in T1DM
    Fanelli, Carmine
    Lucidi, Paola
    Candeloro, Paola
    Cioli, Patrizia
    Andreoli, Anna Marinelli
    Bolli, Geremia B.
    Porcellati, Francesca
    DIABETES, 2018, 67
  • [2] Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
    Heise, Tim
    Norskov, Marianne
    Nosek, Leszek
    Kaplan, Kadriye
    Famulla, Susanne
    Haahr, Hanne L.
    DIABETES OBESITY & METABOLISM, 2017, 19 (07): : 1032 - 1039
  • [3] Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes
    Paola, Lucidi
    Cioli, Patrizia
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Bolli, Geremia B.
    Fanelli, Carmine G.
    Porcellati, Francesca
    DIABETES, 2020, 69
  • [4] Glycaemic variability and risk for hypoglycaemia on insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes
    Kovatchev, B.
    Meng, Z.
    Breton, M.
    Leroy, B.
    Cali, A.
    Perfetti, R.
    DIABETOLOGIA, 2017, 60 : S36 - S37
  • [5] Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation
    Owens, D. R.
    Bailey, T. S.
    Fanelli, C. G.
    Yale, J. -F.
    Bolli, G. B.
    DIABETES & METABOLISM, 2019, 45 (04) : 330 - 340
  • [6] Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
    Steinstraesser, A.
    Schmidt, R.
    Bergmann, K.
    Dahmen, R.
    Becker, R. H. A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (09): : 873 - 876
  • [7] Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats
    Saini, N. K.
    Wasik, B.
    Pires, J.
    Leale, D. M.
    Quach, N.
    Culp, W. T. N.
    Samms, R. J.
    Johnson, A. E.
    Owens, J. G.
    Gilor, C.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2021, 75
  • [8] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA
    Bogdanovic, M.
    Fournier, M.
    Vitezic, D.
    VALUE IN HEALTH, 2018, 21 : S131 - S132
  • [9] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SLOVENIA
    Bogdanovic, M.
    Krnel, Rados S.
    Foumier, M.
    VALUE IN HEALTH, 2017, 20 (09) : A481 - A481
  • [10] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    VALUE IN HEALTH, 2018, 21 : S133 - S133
12345